GeneDx Q2 revenue beats analyst estimates

GeneDx Holdings

03/08/2026 21:12

Overview
U.S. rare disease genomics tester's Q2 revenue grew 11% yr/yr, beating analyst expectations
Adjusted net income was $0.4 mln, up from a loss in the prior quarter
Company reaffirmed full-year 2026 revenue guidance and expanded Medicaid coverage for core tests

Outlook
GeneDx sees full-year 2026 revenue of $475 mln to $490 mln
Company expects third-quarter 2026 revenue of $122 mln to $124 mln
GeneDx projects full-year exome and genome volume growth of at least 30%

Result Drivers
EXOME AND GENOME VOLUME - Q2 exome and genome test volume grew 32% yr/yr, driving revenue growth
EXPANDED COVERAGE - New Medicaid coverage in Texas and California and Carelon policy expanded access to exome and genome sequencing
PRODUCT UPDATES - Redesigned exome and genome reports launched to streamline delivery of genomic insights to clinicians

Company press release: ID:nBw20Jrdpa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$114.40 mln
$111.01 mln (9 Analysts)
Q2 Adjusted Net Income
 
$400,000
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for GeneDx Holdings Corp is $85.00, about 30.5% above its July 31 closing price of $65.11
The stock recently traded at 87 times the next 12-month earnings vs. a P/E of 53 three months ago

Reuters Recommended Reads
Aug 3 - Vertex raises annual revenue forecast on cystic fibrosis drugs strength 
Aug 3 - Curium strikes up to $8 bln deal for radiopharma peer Lantheus
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)